Abstract
Background: Alzheimer's disease (AD) pathology consists of intraneuronal neurofibrillary tangles, made of hyperphosphorylated tau and extracellular accumulation of beta amyloid (Aβ) in Aβ plaques. There is an extensive debate as to which pathology initiates and is responsible for cellular loss in AD.
Methods: Using confocal and light microscopy, post mortem brains from control and AD cases, an antibody to SOD2 as a marker for mitochondria and an antibody to all forms of tau, we analyzed mitochondrial density in tau positive neurons along with nuclear degradation by calculating the raw integrative density.
Results: Our findings showed an extensive staining of aggregated tau in cell bodies, dystrophic neurites and neurofilaments in AD with minimal staining in control tissue, along with a marked decrease in mitochondria in tau positive (tau+) neurons. The control or tau negative (tau-) neurons in AD contained an even distribution of mitochondria, which was greatly diminished in tau+ neurons by 40%. There were no significant differences between control and tau- neurons in AD. Tau+ neurons showed marked nuclear degradation which appeared to progress with the extent of tau aggregation. The aggregated tau infiltrated and appeared to break the nuclear envelope with progressively more DNA exiting the nucleus and associating with the aggregated intracellular tau.
Conclusion: We report that the mitochondrial decrease is likely due to a decrease in the protein synthesis rather than a redistribution of mitochondria because of the decreased axonal transport. We suggest that the decrease in mitochondria and nuclear degradation are key mechanisms for the neuronal loss seen in AD.
Keywords: Mitochondrial loss, SOD2, tau phosphorylation, Alzheimer`s disease, nuclear degradation, decrease in protein synthesis.
Current Alzheimer Research
Title:Tau Positive Neurons Show Marked Mitochondrial Loss and Nuclear Degradation in Alzheimer's Disease
Volume: 15 Issue: 10
Author(s): Melissa Wee, Fariba Chegini, John H.T. Power*Shohreh Majd
Affiliation:
- Neuronal Injury and Repair Laboratory, College of Medicine and Public Health, Flinders University, Adelaide,Australia
Keywords: Mitochondrial loss, SOD2, tau phosphorylation, Alzheimer`s disease, nuclear degradation, decrease in protein synthesis.
Abstract: Background: Alzheimer's disease (AD) pathology consists of intraneuronal neurofibrillary tangles, made of hyperphosphorylated tau and extracellular accumulation of beta amyloid (Aβ) in Aβ plaques. There is an extensive debate as to which pathology initiates and is responsible for cellular loss in AD.
Methods: Using confocal and light microscopy, post mortem brains from control and AD cases, an antibody to SOD2 as a marker for mitochondria and an antibody to all forms of tau, we analyzed mitochondrial density in tau positive neurons along with nuclear degradation by calculating the raw integrative density.
Results: Our findings showed an extensive staining of aggregated tau in cell bodies, dystrophic neurites and neurofilaments in AD with minimal staining in control tissue, along with a marked decrease in mitochondria in tau positive (tau+) neurons. The control or tau negative (tau-) neurons in AD contained an even distribution of mitochondria, which was greatly diminished in tau+ neurons by 40%. There were no significant differences between control and tau- neurons in AD. Tau+ neurons showed marked nuclear degradation which appeared to progress with the extent of tau aggregation. The aggregated tau infiltrated and appeared to break the nuclear envelope with progressively more DNA exiting the nucleus and associating with the aggregated intracellular tau.
Conclusion: We report that the mitochondrial decrease is likely due to a decrease in the protein synthesis rather than a redistribution of mitochondria because of the decreased axonal transport. We suggest that the decrease in mitochondria and nuclear degradation are key mechanisms for the neuronal loss seen in AD.
Export Options
About this article
Cite this article as:
Wee Melissa , Chegini Fariba , Power H.T. John *, Majd Shohreh , Tau Positive Neurons Show Marked Mitochondrial Loss and Nuclear Degradation in Alzheimer's Disease, Current Alzheimer Research 2018; 15 (10) . https://dx.doi.org/10.2174/1567205015666180613115644
DOI https://dx.doi.org/10.2174/1567205015666180613115644 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Synthesis and Some Reactions of 1-aryl-4-acetyl-5-methyl-1,2,3-triazole Derivatives with Anticonvulsant Activity
Mini-Reviews in Medicinal Chemistry Correlation between Blood and Oral Fluid Psychoactive Drug Concentrations and Cognitive Impairment in Driving under the Influence of Drugs
Current Neuropharmacology Synthetic and Natural Immunomodulators Acting as Interferon Inducers
Current Pharmaceutical Design Raman Spectroscopy as a Novel Technology in Forensic Toxicological Analyses
Current Analytical Chemistry Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets Meet Our Section Editor:
Current Medicinal Chemistry Myofascial Temporomandibular Disorder
Current Rheumatology Reviews The Use of TNF Family Ligands and Receptors and Agents which Modify their Interaction as Therapeutic Agents
Current Drug Targets Immunopathology of Type 1 Diabetes and Immunomodulatory Effects of Stem Cells: A Narrative Review of the Literature
Endocrine, Metabolic & Immune Disorders - Drug Targets Interferon Treatment in Patients with Hypereosinophilia
Current Drug Targets Editorial (Thematic Issue: Natural Products in Cancer Prevention and Therapy, a selection of topics presented in the 2nd Edition PSE Symposium (Naples, Italy, 25th to 28th of June 2013))
Anti-Cancer Agents in Medicinal Chemistry Cisplatin Is a DNA-Damaging Antitumour Compound Triggering Multifactorial Biochemical Responses in Cancer Cells: Importance of Apoptotic Pathways
Current Medicinal Chemistry - Anti-Cancer Agents Plant Plastid Engineering
Current Genomics Synthetic and Natural Monoamine Oxidase Inhibitors as Potential Lead Compounds for Effective Therapeutics
Central Nervous System Agents in Medicinal Chemistry The Effect of Cannabis on Perception of Time: A Critical Review
Current Pharmaceutical Design Synthesis and Anthelmintic Evaluation of Novel Valerolactam- Benzimidazole Hybrids
Letters in Drug Design & Discovery VIP in Inflammatory Bowel Disease: State of the Art
Endocrine, Metabolic & Immune Disorders - Drug Targets Pharmacological Manipulation of Neural Progenitor Pathways In Situ: Possibilities for Neural Restoration in the Injured Adult Brain
Current Medicinal Chemistry - Central Nervous System Agents Understanding the Molecular Properties and Metabolism of Top Prescribed Drugs
Current Topics in Medicinal Chemistry Cancer Vaccines in Phase II/III Clinical Trials: State of the Art and Future Perspectives
Current Cancer Drug Targets